TNFSF13B, TNF superfamily member 13b, 10673

N. diseases: 282; N. variants: 13
Disease: B-Cell Lymphomas ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 Biomarker group BEFREE Furthermore, we analyzed the effect of APRIL and BAFF on two B cell lymphoma cell lines using proliferation, viability, and chemotaxis assays. 31615554 2019
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 Biomarker group BEFREE Thus, if this B cell-produced BAFF proves to be actively regulating this same B cell subset, our findings point to an ancient mechanism to control B cell differentiation and survival in lower vertebrates, which has been silenced in mammals in physiological conditions, but reemerges under pathological conditions, such as B cell lymphomas and autoimmune diseases. 28360916 2017
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 AlteredExpression group BEFREE The status of Tfh cell response was assessed by measuring the levels of transcription factor B-cell lymphoma 6 (Bcl-6), interleukin-21 (IL-21), chemokine receptor type 5 (CXCR5), and B-cell-activating factor belonging to the TNF family (BAFF). 27524795 2017
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 Biomarker group BEFREE This study tried to dissect BAFF/BAFF-R-mediated non-canonical NF-κB signaling in the drug resistance of B-cell non-Hodgkin's lymphoma. 27352187 2015
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 AlteredExpression group BEFREE Aberrant BAFF expression was found in malignant B-cells from B-cell non-Hodgkin lymphoma (B-NHL) patients, which protects these cells from spontaneous or drug-induced apoptosis and stimulated NF-κB activation via autocrine and/or paracrine pathways. 24629840 2014
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 Biomarker group BEFREE The selected anti-BAFF antibodies could be candidates for B-cell lymphoma therapies. 24879522 2014
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 AlteredExpression group BEFREE BAFF and APRIL are essential for the survival of normal and malignant B lymphocytes, and altered expression of BAFF or APRIL or of their receptors (BCMA, TACI, or BAFF-R) have been reported in various B-cell malignancies including B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's lymphoma, multiple myeloma, and Waldenstrom's macroglobulinemia. 19291294 2009
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 GeneticVariation group BEFREE Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. 19383901 2009
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 Biomarker group BEFREE Our findings indicate that constitutive NF-kappaB and NFAT activations are crucial transcriptional regulators of the BLyS survival pathway in malignant B cells that could be therapeutic targets in aggressive NHL-B. 16497967 2006
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 Biomarker group BEFREE BAFF is a key factor controlling B cell survival and maturation and its over-expression promotes B cell-mediated autoimmune disorders and participates in the progression of B cell lymphomas. 16931039 2006
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 Biomarker group BEFREE BAFF is also a survival factor for certain B cell lymphomas. 16863659 2006
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 Biomarker group LHGDN Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. 15251985 2004